Bruker Complements Fast, Cost-effective IR Biotyper® Hospital Hygiene Testing and HAI Tracing with NGS Reflex Testing

Bruker Complements Fast, Cost-effective IR Biotyper® Hospital Hygiene Testing and HAI Tracing with NGS Reflex Testing

  • Announces majority investment in NGS bioinformatics solution provider Ridom GmbH
  • New NGS microbiology solutions for hygiene testing and epidemiological studies
  • HAI (Hospital-Acquired Infections) tracing with rapid, cost-effective IR Biotyper® testing, followed by selective NGS reflex testing for confirmation and phylogeny
  • Unique workflow with MALDI Biotyper®-based microbial species identification followed by selective NGS-based strain determination and detailed genomic analysis

VIENNA–(BUSINESS WIRE)–
At the ESCMID Global 2025 conference, Bruker´s Microbiology and Infection Diagnostics division is announcing the expansion of its microbiology solutions into Next-Generation Sequencing (NGS) applications, with new, research-use only NGS-based solutions in epidemiology and hospital acquired infection (HAI) tracing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250411124955/en/

Professor Dag Harmsen, Managing Director of Ridom GmbH

Professor Dag Harmsen, Managing Director of Ridom GmbH

Bruker has entered into a strategic collaboration for NGS bioinformatics applications in microbiology and infectious disease testing with Ridom GmbH, based in Muenster, Germany. Ridom´s NGS bioinformatics software SeqSphere+™ is designed for genomic bacterial strain differentiation, multilocus sequence typing (MLST), core genome MLST (cgMLST), phylogenetic analysis, and real-time clonal and plasmid transmission detection. SeqSphere+ can handle data from various NGS instrument platforms. Ridom is profitable, and financial details of the investment were not disclosed.

The new genomic analysis capabilities are immediately beneficial in hospital hygiene and epidemiological analysis by combining complementary, rapid first-line testing with the cost-effective, short time-to-result IR Biotyper for the detection and rule-out of HAI outbreaks, followed by reflex testing on selected samples by NGS for in-depth phylogenetic analysis. Similarly, important samples can be sequenced after species identification with the MALDI Biotyper to gain genomic insights.

Professor Dag Harmsen, the founder and Managing Director of Ridom, said: “We are delighted to become an important part of Bruker´s Microbiology & Infection Diagnostics solutions. Bruker has a track record of bringing innovation to microbiology, and our new strategic collaboration ensures sustainable service for our NGS customers, and creates new opportunities for our significant growth as part of Bruker´s global microbiology team.”

Professor John Rossen, Professor of Personalized Molecular Microbiology in the Department of Medical Microbiology and Infection Control at the University of Groningen and Isala Hospital Zwolle, The Netherlands, commented: “At our laboratories, we have been working with Ridom’s SeqSphere+ software and the Bruker MALDI Biotyper for many years. I am excited about potential synergies between fast microbial identification and in-depth genomic information in order to provide, for example, further insights into the spreading of antibiotic resistances.”

Dr. Wolfgang Pusch, President of Bruker´s Microbiology & Infection Diagnostics Division, added: “Since the introduction of our MALDI Biotyper for fast, near-universal microbial identification from cultures, we are committed to bringing innovations to microbiology. The novel, research-use only combination of our IR Biotyper for rapid, cost-effective and strain-specific detection or rule-out of hospital outbreaks, in combination with NGS reflex testing for genomic interpretation with SeqSphere+, provides a unique triage offering for epidemiology and healthcare acquired infection tracing.”

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Trade Press & Customer Contact:

Philip Perry

Senior Vice-President, Marketing and Product Management

Bruker Microbiology & Infection Diagnostics Division

T: +49-172-313-7216

E: [email protected]

Investor Contact:

Joe Kostka

Director, Investor Relations

Bruker Corporation

T: +1 (978) 313-5800

E: [email protected]

 

KEYWORDS: Austria Europe Germany

INDUSTRY KEYWORDS: Genetics Clinical Trials Health Technology Biotechnology Health Pharmaceutical General Health Other Science Science

MEDIA:

Photo
Photo
Professor Dag Harmsen, Managing Director of Ridom GmbH
Photo
Photo
SeqSphere analysis and visualization of place, time, sample, and type (including sequences) of a Listeria monocytogenes outbreak
Logo
Logo

Lost Money on SoundHound AI, Inc.(SOUN)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

PR Newswire


NEW YORK
, April 11, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in SoundHound AI, Inc. (“SoundHound AI, Inc.” or the “Company”) (NASDAQ: SOUN) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of SoundHound AI, Inc. investors who were adversely affected by alleged securities fraud between May 10, 2024 and March 3, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/soundhound-ai-inc-lawsuit-submission-form?prid=142253&wire=4

SOUN investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) the material weaknesses in SoundHound’s internal controls over financial reporting impaired the Company’s ability to effectively account for corporate acquisitions; (ii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal controls over financial reporting; (iii) as a result of the foregoing material weaknesses, SoundHound’s reported goodwill following the Amelia Acquisition was inflated and would need to be corrected; (iv) further, SoundHound would likely require extra time and expense to effectively account for the SYNQ3 and Amelia Acquisitions; (v) the foregoing increased the risk that the Company would be unable to timely file certain financial reports with the SEC; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.

WHAT’S NEXT? If you suffered a loss in SoundHound AI, Inc. during the relevant time frame, you have until May 27, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lost-money-on-soundhound-ai-incsoun-join-class-action-suit-seeking-recovery–contact-levi–korsinsky-302426148.html

SOURCE Levi & Korsinsky, LLP

Class Action Filed Against Sana Biotechnology, Inc. (SANA) Seeking Recovery for Investors – Contact Levi & Korsinsky

PR Newswire


NEW YORK
, April 11, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. (“Sana Biotechnology, Inc.” or the “Company”) (NASDAQ: SANA) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=142249&wire=4

SANA investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Sana was at significant risk of having insufficient funds to maintain its current operations and advance one or more of its product candidates; (ii) SC291 in oncology, SC379, and SG299 were less promising than defendants had led investors to believe; (iii) in order to preserve cash and advance its more promising product candidates, Sana was likely to decrease funding for and/or discontinue SC291 in oncology, SC379, and SG299, as well as significantly reduce its headcount; (iv) accordingly, defendants overstated Sana’s financial capacity to maintain its current operations and advance its existing product candidates; and (v) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

WHAT’S NEXT? If you suffered a loss in Sana Biotechnology, Inc. during the relevant time frame, you have until May 20, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/class-action-filed-against-sana-biotechnology-inc-sana-seeking-recovery-for-investors–contact-levi–korsinsky-302426174.html

SOURCE Levi & Korsinsky, LLP

Shareholders of Solaris Energy Infrastructure, Inc. Should Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights – SEI

PR Newswire


NEW YORK
, April 11, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Solaris Energy Infrastructure, Inc. (“Solaris Energy Infrastructure, Inc.” or the “Company”) (NYSE: SEI) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Solaris Energy Infrastructure, Inc. investors who were adversely affected by alleged securities fraud between July 9, 2024 and March 17, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/solaris-energy-infrastructure-inc-lawsuit-submission-form?prid=142254&wire=4 

SEI investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) MER, Mobile Energy Rentals LLC, had little to no corporate history in the mobile turbine leasing space; (2) MER did not have a diversified earnings stream; (3) MER’s co-owner was a convicted felon associated with multiple allegations of turbine-related fraud; (4) as a result, Solaris overstated the commercial prospects posed by the Acquisition; (5) Solaris inflated profitability metrics by failing to properly depreciate its turbines; and (6) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT’S NEXT? If you suffered a loss in Solaris Energy Infrastructure, Inc. during the relevant time frame, you have until May 27, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholders-of-solaris-energy-infrastructure-inc-should-contact-levi–korsinsky-before-may-27-2025-to-discuss-your-rights–sei-302426156.html

SOURCE Levi & Korsinsky, LLP

May 20, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against PPTA

PR Newswire


NEW YORK
, April 11, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Perpetua Resources Corp. (“Perpetua Resources Corp.” or the “Company”) (NASDAQ: PPTA) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Perpetua Resources Corp. investors who were adversely affected by alleged securities fraud between April 17, 2024 and February 13, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/perpetua-resources-corp-lawsuit-submission-form?prid=142250&wire=4

PPTA investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Perpetua’s expected initial capital expenditure for the Stibnite Gold Project. Defendants’ statements included, among other things, minimization of the impact of inflation and other potential sources for increased capital expenditure costs for the project.   On February 13, 2025, Perpetua published an updated cash flow model for the Stibnite Gold Project, unveiling additional capital expenses of $952 million, a more than 75% increase from the original figures presented to investors and well beyond the suggested 10-20% increase contemplated by defendants. The Company attributed these increased costs on inflation, indirect costs, higher mining costs, and direct decisions defendants made with respect to the project, including the choice to change the design of the electrical poles from timber to steel and the decision to “buy-and-build instead of lease the oxygen plant.”  Following this news, the price of Perpetua’s common stock declined dramatically. From a closing market price of $11.97 per share on February 13, 2025, Perpetua’s stock price fell to $9.29 per share on February 14, 2025, a decline of about 22.39% in the span of just a single day.

WHAT’S NEXT? If you suffered a loss in Perpetua Resources Corp. during the relevant time frame, you have until May 20, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/may-20-2025-deadline-contact-levi–korsinsky-to-join-class-action-suit-against-ppta-302426171.html

SOURCE Levi & Korsinsky, LLP

Investors in Everus Construction Group, Inc. Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights – ECG

PR Newswire


NEW YORK
, April 11, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Everus Construction Group, Inc. (“Everus Construction ” or the “Company”) (NYSE: ECG) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Everus Construction investors who were adversely affected by alleged securities fraud between October 31, 2024 and February 11, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/everus-construction-group-inc-lawsuit-submission-form?prid=142256&wire=4

ECG investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) the Company’s backlog conversion cycle had become elongated due to larger, more complex projects; (2) as a result, the Company’s revenue recognition would be delayed; and (3) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT’S NEXT? If you suffered a loss in Everus Construction during the relevant time frame, you have until June 3, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investors-in-everus-construction-group-inc-should-contact-levi–korsinsky-before-june-3-2025-to-discuss-your-rights–ecg-302426088.html

SOURCE Levi & Korsinsky, LLP

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

PR Newswire


NEW YORK
, April 11, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE: ATNM) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=142252&wire=4

ATNM investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) the Company’s data from the Phase 3 Sierra trial was unlikely to satisfy the FDA’s guidelines for the acceptance and approval of the Company’s targeted radiotherapy, Iomab-B BLA; (2) the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival that the Company provided to the FDA in an attempt to mitigate the Sierra Trial’s poor OS data were unlikely to satisfy the FDA’s guidelines for the acceptance and approval of the Company’s Iomab-B BLA; (3) as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved; and (4), as a result, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT’S NEXT? If you suffered a loss in Actinium during the relevant time frame, you have until May 27, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/levi–korsinsky-reminds-shareholders-of-a-lead-plaintiff-deadline-of-may-27-2025-in-actinium-lawsuit–atnm-302426089.html

SOURCE Levi & Korsinsky, LLP

Investors who lost money on TFI International Inc.(TFII) should contact Levi & Korsinsky about pending Class Action – TFII

PR Newswire


NEW YORK
, April 11, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in TFI International Inc. (“TFI International Inc.” or the “Company”) (NYSE: TFII) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of TFI International Inc. investors who were adversely affected by alleged securities fraud between April 26, 2024 and February 19, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/tfi-international-inc-lawsuit-submission-form?prid=142246&wire=4

TFII investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) the Company was losing small and medium business customers; (2) as a result, the Company’s TForce revenue was declining; (3) TFI was experiencing difficulties managing its costs; (4) as a result of the foregoing, the profitability of its largest business segment was declining; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT’S NEXT? If you suffered a loss in TFI International Inc. during the relevant time frame, you have until May 13, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investors-who-lost-money-on-tfi-international-inctfii-should-contact-levi–korsinsky-about-pending-class-action—tfii-302426164.html

SOURCE Levi & Korsinsky, LLP

Fluence Energy, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before May 12, 2025 to Discuss Your Rights – FLNC

PR Newswire


NEW YORK
, April 11, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Fluence Energy, Inc. (“Fluence Energy” or the “Company”) (NASDAQ: FLNC) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fluence Energy investors who were adversely affected by alleged securities fraud between November 29, 2023 and February 10, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/fluence-energy-lawsuit-submission-form?prid=142244&wire=4

FLNC investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Fluence’s relationship with its founders and largest sources of revenue, Siemens AG and The AES Corporation, was poised to decline; (2) Siemens Energy, Siemens AG’s U.S. affiliate, had accused the Company of engineering failures and fraud; (3) Fluence’s margins and revenue growth were inflated as Siemens and AES were moving to divest; and (4) based on the foregoing, defendants lacked a reasonable basis for their positive statements related to Fluence’s battery energy storage business, as well as related financial results, growth, and prospects.

WHAT’S NEXT? If you suffered a loss in Fluence Energy during the relevant time frame, you have until May 12, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/fluence-energy-inc-sued-for-securities-law-violations–investors-should-contact-levi–korsinsky-before-may-12-2025-to-discuss-your-rights–flnc-302426163.html

SOURCE Levi & Korsinsky, LLP

Class Action Filed Against Maravai LifeSciences Holdings, Inc. (MRVI) Seeking Recovery for Investors – Contact Levi & Korsinsky

PR Newswire


NEW YORK
, April 11, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Maravai LifeSciences Holdings, Inc. (“Maravai LifeSciences” or the “Company”) (NASDAQ: MRVI) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Maravai LifeSciences investors who were adversely affected by alleged securities fraud between August 7, 2024 and February 24, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/maravai-lifesciences-holdings-inc-lawsuit-submission-form?prid=142242&wire=4

MRVI investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Maravai lacked adequate internal controls over financial reporting related to revenue recognition; (2) as a result, the Company inaccurately recognized revenue on certain transactions during fiscal 2024; (3) its goodwill was overstated; and (4)as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT’S NEXT? If you suffered a loss in Maravai LifeSciences during the relevant time frame, you have until May 5, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/class-action-filed-against-maravai-lifesciences-holdings-inc-mrvi-seeking-recovery-for-investors–contact-levi–korsinsky-302426162.html

SOURCE Levi & Korsinsky, LLP